Skip to content

Sofosbuvir + ribavirin is safe and effective for HCV recurrence after liver transplantation

Voucher incentives improve engagement with HIV care among people who inject drugs

Sustained response to treatment reduces fatigue in hepatitis C patients

Investigational protease inhibitor TMC310911 highly potent in phase 2 study

Sofosbuvir + ribavirin for 24 weeks is highly effective against HCV genotype 4

Early antiretroviral treatment reduces risk of AIDS and HIV-related illness

PCR testing reveals high prevalence of CNS infections among people living with HIV in Zambia with CNS symptoms

Methadone and buprenorphine-naloxone both associated with reduced HIV risk among people who inject drugs

Implementation of a comprehensive harm reduction programme curtailed the HIV epidemic among people who inject drugs in Taiwan